Nonalcoholic steatohepatitis (NASH)
It is estimated that by 2030, NASH will be the #1 most frequent reason for liver transplants in the US

NASH Epidemic & the Need for the ELF Test

The Need for Noninvasive Liver Fibrosis Tests

Assessment of liver fibrosis has traditionally relied on costly and invasive liver biopsy that requires a specialist, may not be representative of the amount of fibrosis, and carries a risk of life-threatening complications.

Identify risk of disease progression in advanced fibrosis due to NASH with a simple blood test

The ELF^TM Test is a routine blood test proven to predict progression to cirrhosis and liver related events in patient with advanced fibrosis due to NASH¹

The only blood test with a prognostic claim in advanced fibrosis due to NASH
Simplifies and accelerates the identification of patients with advanced fibrosis due to NASH, at risk of disease progression
Facilitates more frequent prognostic assessments
Available to all patients

The ELF Test enables accessible, effortless prognostic risk assessment in advanced fibrosis due to NASH, improving patient care by stratifying those most at risk of progressing to cirrhosis and liver related events¹

Download infographic (pdf)

Learn more

For Patients: Liver disease is a silent killer. Are you at risk?

Tony Villioti is a liver transplant recipient and cancer survivor. Watch his story to learn about why early detection and intervention are critical in the battle against liver disease.